Radiotherapy is a cornerstone of modern oncology, yet its clinical success is frequently curtailed by radioresistance—the ability of tumor cells to survive and even thrive after exposure to ionizing radiation. This resistance leads to local recurrence, metastasis, and treatment failure in aggressive malignancies ranging from non-small cell lung cancer (NSCLC) to nasopharyngeal carcinoma.
Current research focuses on identifying the molecular "switches" that govern this survival and developing radiosensitizers: agents that prime cancer cells to be more vulnerable to radiation without increasing systemic toxicity.
Trapping Cells in Vulnerable States
The cell cycle is a primary determinant of radiation sensitivity. Cells are most vulnerable to DNA damage during the G2/M phase. Many tumors develop resistance by bypassing these checkpoints or lingering in more resistant phases.
Researchers are exploring ways to "trap" cells in this vulnerable state. Jia Liu and colleagues demonstrated that Fenofibrate, a common cholesterol drug, can downregulate CDK1 and Cyclin B1, inducing G2/M arrest and significantly increasing radiosensitivity in head and neck squamous cell carcinoma (Fenofibrate Increases Radiosensitivity in Head and Neck Squamous Cell Carcinoma via Inducing G2/M Arrest and Apoptosis). Similarly, Ran Yang developed a cisplatin-encapsulated nanoplatform that synchronizes cells into the G2/M phase, creating a synergistic lethal effect when combined with radiation (Cisplatin-encapsulated zeolitic imidazolate framework-8 nanosystem enhanced radiosensitivity of non-small cell lung cancer).
Breaking the DNA Repair Machinery
Radiation kills by shattering DNA. Radioresistant cells, however, possess hyper-active repair mechanisms. The ATM/ATR signaling axis acts as a master regulator of this repair.
In osteosarcoma, Yao Lu identified a "molecular switch" involving the FBXO32/ATR/ATM axis that controls the expression of the DNA repair protein EXO1 (The FBXO32/ATR/ATM axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression). Other researchers have found that tumors hijack specific proteins to shield their DNA. For instance, Chen Tian found that ADAR1 interacts with Rad18 to accelerate DNA repair in lung cancer (ADAR1 enhances tumor proliferation and radioresistance in non-small cell lung cancer by interacting with Rad18), while Enni Chen showed that the transcription factor FLI1 activates the PI3K/AKT pathway to speed up repair in nasopharyngeal carcinoma (FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway).
Metabolic and Microenvironmental Priming
The environment surrounding a tumor—its metabolism and its oxygen levels—dictates its survival. Hypoxia (low oxygen) is a notorious driver of radioresistance because oxygen is required to "fix" radiation-induced DNA damage into permanent breaks.
Hongcheng Zhu and Xi Yang demonstrated that normalizing tumor vasculature with recombinant human endostatin can reduce hypoxia, thereby "priming" esophageal tumors for a better radioresponse (Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia).
Metabolically, tumors often rely on glycolysis to fuel the energy-intensive process of repairing radiation damage. Baoyu He identified a long noncoding RNA (LINC00930) that drives this "glycolytic switch" (Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma). Conversely, natural compounds like Phloretin, found in apples, have been shown by Juan Tang to stunt tumor growth by inhibiting the glucose uptake necessary for survival (Combination treatment with Phloretin enhances the anti-tumor efficacy of radiotherapy in lung cancer models).
Communication and External Factors
Radioresistance is not always an intrinsic property of a single cell; it can be "shared" across the tumor microenvironment. Jincheng Fang and colleagues have highlighted the role of exosomes—microscopic cargo ships—that transport microRNAs and proteins between cells to coordinate DNA repair and immune evasion (Role of exosomes in modulating non-small cell lung cancer radiosensitivity).
Even environmental pollutants can play a role. Hailong Sheng recently discovered that polyvinyl chloride (PVC) microplastics can infiltrate liver tumors and inhibit the differentiation of CD8⁺ T cells, effectively shielding the tumor from the immune-boosting effects of radiotherapy (Polyvinyl Chloride Promotes Radioresistance in Hepatocellular Carcinoma by Inhibiting Radiotherapy-Induced CD8⁺ T Cell Differentiation).
By mapping these diverse pathways—from cell cycle checkpoints and DNA repair axes to metabolic shifts and exosomal communication—researchers are moving toward a personalized approach to radiotherapy where resistance is predicted by biomarkers and overcome by targeted sensitizers.